Isomorphic Labs, Alphabet's AI-powered drug discovery company led by Nobel laureate Demis Hassabis, completed a $5 billion Series C funding round co-led by Greenoaks and Sequoia Capital. New investors including Andreessen Horowitz (a16z) joined the round, while Alphabet continued its substantial capital commitment alongside existing backers Thrive Capital, MGX, GV, CapitalG, Temasek, and the UK Sovereign AI Fund.
The company plans to deploy the capital to advance foundational simulation models, scale internal and partnered drug candidate programs, and build global AI-driven bioengineering infrastructure.
Isomorphic Labs Raises $5B Series C Co-Led by Sequoia Capital and Greenoaks
Disclaimer: The content provided on Phemex News is for informational purposes only. We do not guarantee the quality, accuracy, or completeness of the information sourced from third-party articles. The content on this page does not constitute financial or investment advice. We strongly encourage you to conduct you own research and consult with a qualified financial advisor before making any investment decisions.
